Scientists have transplanted gene-edited insulin-producing cells into a human patient with type 1 diabetes. A 42-year-old man, who has lived with type 1 diabetes for most of his life, became the first person to receive nearly 80 million genetically modified pancreatic cells implanted into his forearm muscle.
The cells were engineered with CRISPR-Cas12b technology, a modern gene-editing tool, to hide from the patient’s immune system. Normally, transplanted cells are quickly destroyed by immune attacks, and patients must take powerful drugs to prevent rejection. But this new approach allowed the cells to survive without the need for lifelong immunosuppressants.
“This is the most exciting moment of my scientific career,” said Per-Ola Carlsson, a cell biologist at Uppsala University in Sweden who helped lead the project. “The treatment opens the future possibility of not only treating diabetes but also other autoimmune diseases. We are taking the first step toward something that was once thought impossible.”
After 12 weeks, doctors confirmed that the cells were still alive and working. The man’s blood sugar control improved significantly, with his HbA1c levels dropping by around 42 percent. The transplanted cells were able to release insulin after meals, although the patient still needed additional insulin because the first dose of cells was relatively small.
The case has been published in the New England Journal of Medicine and is being closely watched by the global medical community. Scientists say the patient will be closely monitored for at least a year to track the long-term safety and effectiveness of the therapy.
Type 1 diabetes affects nearly 9.5 million people worldwide, including about two million in the United States alone. The disease occurs when the immune system mistakenly destroys islet cells in the pancreas that are responsible for producing insulin, a hormone that regulates blood sugar levels. Without insulin, patients must rely on daily injections or pumps for survival.
The recipient, who asked not to be identified publicly, reportedly told researchers that the transplant has given him “a new sense of hope” after decades of struggling with daily injections and strict blood sugar monitoring. “If this really works in the future,” he said, “it could change the lives of millions like me.”
Type 1 diabetes affects around two million people in the United States and about 9.5 million globally. It develops when the body’s immune system mistakenly destroys islet cells in the pancreas that are responsible for making insulin, the hormone needed to control blood sugar.
Without insulin, blood sugar levels rise dangerously, leading to severe health problems such as heart disease, kidney damage, nerve issues, and even blindness.
For patients, the reality is a lifetime of insulin injections or pumps, often multiple times a day, along with constant blood sugar checks. While treatments have improved, there has never been a cure.
Past attempts at pancreatic cell transplants often failed because the immune system quickly attacked the donor cells, forcing patients to take immunosuppressive drugs. Those drugs lower immunity, leaving patients vulnerable to infections and cancer.
“This new method avoids that,” explained one of the U.S. researchers involved in the trial. “By editing the cells themselves, we make them invisible to the immune system, so patients don’t need dangerous drugs. That is what makes this such a game changer.”
CRISPR technology has already been used in experimental treatments for cancer, genetic disorders, and rare diseases. In this case, researchers used it to make three changes to the donor pancreatic cells. Two edits reduced the proteins that usually signal immune cells to attack, while another edit increased the production of a protective protein called CD47, which sends a “don’t harm me” signal to the body.
The result was a set of insulin-producing cells that the patient’s immune system ignored. Scientists then injected the cells into the man’s forearm muscle, where they took hold and began releasing insulin.
Researchers stress that this is an early-stage study with just one patient, and the dose of cells given was relatively small. The patient still needs insulin injections, but larger trials with higher doses could reduce or even eliminate the need for insulin in the future.
“We are witnessing the early days of what could become a revolution in regenerative medicine,” said one endocrinologist not involved in the study. “But we must wait for more data. The long-term survival of these cells is the real test.”
The research team plans to continue following the patient for the full year and then expand the study to more people. If larger trials confirm the success, the therapy could change the way type 1 diabetes is managed. For patients, it could mean fewer injections, more stable blood sugar control, and, one day, freedom from insulin altogether.
